HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Judith Bushong Selected Research

Immunotherapy

10/2023Association between pathologic response and survival after neoadjuvant therapy in lung cancer.
1/2023Systemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1.
1/2023Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Judith Bushong Research Topics

Disease

5Neoplasms (Cancer)
10/2023 - 01/2022
3Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
10/2023 - 01/2023
1Pathologic Complete Response
10/2023
1Lung Neoplasms (Lung Cancer)
10/2023
1Brain Neoplasms (Brain Tumor)
01/2023
1Neoplasm Metastasis (Metastasis)
01/2023
1Exanthema (Rash)
01/2022

Drug/Important Bio-Agent (IBA)

6NivolumabIBA
10/2023 - 01/2022
5IpilimumabIBA
10/2023 - 01/2022
4B7-H1 AntigenIBA
10/2023 - 01/2022
1Proteins (Proteins, Gene)FDA Link
10/2023
1Adrenal Cortex Hormones (Corticosteroids)IBA
01/2022

Therapy/Procedure

5Drug Therapy (Chemotherapy)
10/2023 - 01/2022
3Immunotherapy
10/2023 - 01/2023
1Neoadjuvant Therapy
10/2023